Estamos no ar no ! Saiba mais

OneMedNet

ONMD

Valor de mercado US$ 26,3 mi

4,51 USD

-0,24

5,05%

No fechamento Atualizado 16 de out. 16:00 EDT

1 dia

-5,05%

5 dias

7,89%

1 mês

-26,67%

3 meses

-34,64%

6 meses

-49,15%

No acumulado do ano

-63,03%

1 ano

-82,45%

5 anos

-95,51%

10 anos

-95,44%

Sobre: OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.

Funcionários: 23

Saúde Serviços de informação em saúde

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 0%

Neutro 100%

Negativo 0%

OneMedNet Adds Leading Hospital System Provider Network, Expanding By Up to 12 Hospitals

MINNEAPOLIS, Oct. 15, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced the addition of a leading hospital system to its iRWD™ platform and federated provider network and expects to expand the network by up to 12 additional hospitals. The new partnership meaningfully expands both the scale and more importantly clinical depth of OneMedNet's healthcare data network.

OneMedNet Adds Leading Hospital System Provider Network, Expanding By Up to 12 Hospitals

OneMedNet Signs Mediplexus as its 11th Channel Partner, Expanding the Company's Real World Data Footprint into Korea and the Asia Pacific Region

MINNEAPOLIS, Oct. 07, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real World Data (RWD), today announced its 11th channel partner agreement with Mediplexus, a healthcare data company specializing in RWD and Real World Evidence (RWE) and a subsidiary of C&R Research, one of Korea's leading contract research organizations (CROs). Under the agreement, OneMedNet will supply its U.S.-sourced Real World Data to Mediplexus, its appointed distributor in Korea – extending OneMedNet's commercial reach into the broader Asia Pacific region.

OneMedNet Signs Mediplexus as its 11th Channel Partner, Expanding the Company's Real World Data Footprint into Korea and the Asia Pacific Region

OneMedNet Signs Seven Figure Multiyear Agreement to Power a Partner Sold Derivative Data Solution

MINNEAPOLIS, Sept. 30, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real World Data (RWD), today announced a seven figure multiyear agreement to deliver de-identified, multimodal, longitudinal clinical Real World Data to a commercially scaled AI-enabled precision medicine company.

OneMedNet Signs Seven Figure Multiyear Agreement to Power a Partner Sold Derivative Data Solution

OneMedNet Corporation Announces 1-for-10 Reverse Stock Split

MINNEAPOLIS, Sept. 25, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “Company,” “we,” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced that it will implement a 1-for-10 reverse stock split of its issued and outstanding shares of common stock (the “Reverse Stock Split”), effective at 12:01 a.m.

OneMedNet Corporation Announces 1-for-10 Reverse Stock Split

Atropos Health Scales Federated Evidence Network with Multimodal Data Partners to Accelerate Health Analytics and AI Model Development

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in real-world evidence (RWE) generation from high-quality healthcare data, today announced a significant expansion of its federated Atropos Evidence™ Network. The expansion includes deeper collaborations with Norstella and Arcadia, along with new data partnership agreements with OneMedNet Corporation (Nasdaq: ONMD). These alliances extend the scope of Atropos Health's data ecosystem across clinical decision support (CDS), model traini.

Atropos Health Scales Federated Evidence Network with Multimodal Data Partners to Accelerate Health Analytics and AI Model Development

OneMedNet Expands Commercial Reach Through Multi-Year Resale Agreement with Atropos Health

MINNEAPOLIS, Sept. 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us,” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), today announced a strategic partnership with Atropos Health, the creator of real-world evidence for clinical decision-making under a multi-year agreement.

OneMedNet Expands Commercial Reach Through Multi-Year Resale Agreement with Atropos Health

OneMedNet Reports Record Bookings as Faster Fulfillment Begins

MINNEAPOLIS, Sept. 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced year-to-date bookings of approximately $16.2 million, a 16X increase versus the same period in 2025.

OneMedNet Reports Record Bookings as Faster Fulfillment Begins

OneMedNet's iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company

MINNEAPOLIS, Aug. 31, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced a new agreement to deliver de-identified, full-fidelity clinical Real-World Data to a leading AI-driven drug development company. OneMedNet's iRWD™ Platform enabled cohort feasibility within minutes, data validation within a week, and signed contract within three weeks of initial contact, and is now delivering the data to support the customer's development and validation of AI models designed to accelerate and improve how new therapies are discovered and developed.

OneMedNet's iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company

OneMedNet Secures $11.5+ Million Agreement to Supply Regulatory-Grade Real-World Data for Foundational AI Model Development

MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), today announced it has entered into an agreement to supply its regulatory-grade, multi-modal imaging-centric iRWD™ platform data for use in the development and training of a foundational AI model. Under the terms of the agreement, OneMedNet will provide high-quality, de-identified, regulatory-grade healthcare data, including millions of medical imaging and associated clinical reports, with data delivery immediately.

OneMedNet Secures $11.5+ Million Agreement to Supply Regulatory-Grade Real-World Data for Foundational AI Model Development

OneMedNet Executes on Growth Strategy: Secures Over $3 Million in New Bookings, Surpassing Full-Year 2025

MINNEAPOLIS, June 10, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), today announced it has secured more than $3 million in new bookings to date for 2026 as of this announcement – surpassing the Company's total bookings for all of full-year 2025. The Company expects to recognize substantially all of these bookings as revenue by the end of the third quarter of 2026.

OneMedNet Executes on Growth Strategy: Secures Over $3 Million in New Bookings, Surpassing Full-Year 2025

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™